FI962593A0 - Lisäkilpirauhasen hormonikoostumukset - Google Patents

Lisäkilpirauhasen hormonikoostumukset

Info

Publication number
FI962593A0
FI962593A0 FI962593A FI962593A FI962593A0 FI 962593 A0 FI962593 A0 FI 962593A0 FI 962593 A FI962593 A FI 962593A FI 962593 A FI962593 A FI 962593A FI 962593 A0 FI962593 A0 FI 962593A0
Authority
FI
Finland
Prior art keywords
parathyroid hormone
excipient
hormone compositions
buffering agent
compositions
Prior art date
Application number
FI962593A
Other languages
English (en)
Swedish (sv)
Other versions
FI962593A (fi
FI120291B (fi
Inventor
Josephus Johannes Mar Holthuis
Albert Mekking
Alwinus Antonius Voetman
Original Assignee
Allelix Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allelix Biopharma filed Critical Allelix Biopharma
Publication of FI962593A0 publication Critical patent/FI962593A0/fi
Publication of FI962593A publication Critical patent/FI962593A/fi
Application granted granted Critical
Publication of FI120291B publication Critical patent/FI120291B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FI962593A 1993-12-23 1996-06-20 Lisäkilpirauhasen hormoniformulaation valmistusmenetelmä FI120291B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17220693 1993-12-23
US08/172,206 US5496801A (en) 1993-12-23 1993-12-23 Parathyroid hormone formulation
CA9400693 1994-12-16
PCT/CA1994/000693 WO1995017207A1 (en) 1993-12-23 1994-12-16 Parathyroid hormone formulation

Publications (3)

Publication Number Publication Date
FI962593A0 true FI962593A0 (fi) 1996-06-20
FI962593A FI962593A (fi) 1996-08-19
FI120291B FI120291B (fi) 2009-09-15

Family

ID=22626763

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962593A FI120291B (fi) 1993-12-23 1996-06-20 Lisäkilpirauhasen hormoniformulaation valmistusmenetelmä

Country Status (23)

Country Link
US (1) US5496801A (fi)
EP (2) EP1880732A1 (fi)
JP (1) JP3065662B2 (fi)
KR (1) KR100398461B1 (fi)
CN (1) CN1116897C (fi)
AT (1) ATE374621T1 (fi)
AU (1) AU681737B2 (fi)
BR (1) BR9408398A (fi)
CA (1) CA2179207C (fi)
CZ (1) CZ184296A3 (fi)
DE (1) DE69435033T2 (fi)
DK (1) DK0735896T3 (fi)
ES (1) ES2293637T3 (fi)
FI (1) FI120291B (fi)
HK (1) HK1010336A1 (fi)
HU (1) HUT74381A (fi)
LV (1) LV11731B (fi)
NO (1) NO324905B1 (fi)
NZ (1) NZ277463A (fi)
PL (1) PL315158A1 (fi)
PT (1) PT735896E (fi)
SK (1) SK82896A3 (fi)
WO (1) WO1995017207A1 (fi)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011785A1 (en) * 1991-12-09 1993-06-24 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
US6509316B2 (en) * 1995-03-07 2003-01-21 George Washington University Pharmaceutical compositions, methods, and kits for treatment and diagnosis of lung cancer
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP1016412A4 (en) * 1997-07-22 2001-05-02 Chugai Pharmaceutical Co Ltd DENTISTRY WITH PTH
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
ZA9811127B (en) * 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
ID25660A (id) * 1997-12-18 2000-10-19 Lilly Co Eli Teripatide kristal
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
JP4486256B2 (ja) * 1998-10-22 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体
WO2000032771A1 (en) * 1998-11-30 2000-06-08 The General Hospital Corporation Pth1r and pth3r receptors, methods and uses thereof
US7820393B2 (en) * 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
WO2004028444A2 (en) * 1999-06-02 2004-04-08 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
BR0013162A (pt) * 1999-07-12 2002-05-28 Grandis Biotech Gmbh Formulações de hormÈnio de crescimento
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
AU783952B2 (en) 2000-02-04 2006-01-05 Unigene Laboratories, Inc. Nasal calcitonin formulations
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
US6387711B1 (en) * 2000-08-11 2002-05-14 Quest Diagnostics Investments Incorporated Liquid intact parathyroid hormone (PTH) standards
US6905886B2 (en) * 2000-08-11 2005-06-14 Quest Diagnostics Investments Incorporated Preservative solutions
US7226442B2 (en) * 2000-10-10 2007-06-05 Microchips, Inc. Microchip reservoir devices using wireless transmission of power and data
KR100491737B1 (ko) * 2001-07-20 2005-05-27 주식회사 한국아이템개발 공기 정화 기능의 모기 퇴치기
WO2003009804A2 (en) 2001-07-23 2003-02-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US20040067526A1 (en) * 2002-10-03 2004-04-08 Cantor Thomas L. Methods for diagnosing and guiding treatment of bone turnover disease
US7795220B2 (en) * 2003-03-19 2010-09-14 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
JP5456234B2 (ja) 2003-06-30 2014-03-26 アルザ・コーポレーシヨン 非揮発性の対イオンを含有する被覆された微小突起のための製剤
KR100540659B1 (ko) * 2003-07-02 2006-01-10 삼성전자주식회사 이미지 확대 인쇄 방법과 장치 및 컴퓨터 프로그램을저장하는 컴퓨터로 읽을 수 있는 기록 매체
US20050032698A1 (en) * 2003-07-14 2005-02-10 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
EP1653985A4 (en) 2003-07-17 2009-08-05 Gen Hospital Corp CONSTRAINTS CONTAINING CONTAINING HORMONE PARATHYROID (PTH) ANALOGUES
US7459276B2 (en) * 2003-09-29 2008-12-02 Scantibodies Laboratory, Inc. Methods and controls for monitoring assay quality and accuracy in parathyroid hormone measurement
US20050119183A1 (en) * 2003-11-12 2005-06-02 Nps Allelix Corp. Method for treating bone loss using parathyroid hormone
CN100548228C (zh) * 2003-11-13 2009-10-14 阿尔扎公司 用于透皮递送的组合物和装置
CN100406059C (zh) * 2004-04-30 2008-07-30 陈新梅 甲状旁腺激素的新用途
BRPI0509788A (pt) * 2004-05-13 2007-10-23 Alza Corp aparato e método para liberação transdérmica de agentes de hormÈnio paratireóides
US7541140B2 (en) * 2004-06-03 2009-06-02 Scantibodies Laboratory, Inc. Assessing risk for kidney stones using parathyroid hormone agonist and antagonist
US20080076975A1 (en) * 2005-01-25 2008-03-27 Microchips, Inc. Method and implantable device with reservoir array for pre-clinical in vivo testing
WO2006081279A2 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
KR100700869B1 (ko) 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
JP2009515535A (ja) * 2005-11-10 2009-04-16 ボード オブ コントロール オブ ミシガン テクノロジカル ユニヴァーシティー クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
JP2009545320A (ja) * 2006-08-04 2009-12-24 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
MX353986B (es) 2007-08-01 2017-11-06 Massachusetts Gen Hospital Metodos de analisis y seleccion usando receptores acoplados a proteina g y composiciones relacionadas.
WO2009019715A1 (en) * 2007-08-09 2009-02-12 Usv Limited Novel orthogonal process for purification of recombinant human parathyroid hormone (rhpth) (1-34)
JP2009091363A (ja) * 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Ｐｔｈの安定化水溶液注射剤
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
MX358161B (es) 2010-05-13 2018-08-06 The General Hospital Corp Star Analogos de hormona paratiroidea y usos para los mismos.
EA028572B1 (ru) * 2011-03-10 2017-12-29 Ксерис Фармасьютикалс, Инк. Стабильная композиция для парентеральной инъекции и способы ее получения и использования
KR20150116467A (ko) * 2011-06-07 2015-10-15 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
JP2016512839A (ja) * 2013-03-15 2016-05-09 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 治療物質の送達のための生体内分解性ケイ素系組成物
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
KR20210038618A (ko) * 2018-07-30 2021-04-07 샤이어-엔피에스 파마슈티칼즈, 인크. 재조합 인간 부갑상선 호르몬의 개선된 안정성을 위한 제형
CN110917150A (zh) * 2019-12-31 2020-03-27 北京博康健基因科技有限公司 一种pth冻干制剂及其制备方法
KR20220160676A (ko) * 2020-03-30 2022-12-06 쓰촨 루저우 부창 바이오-파마슈티컬 컴퍼니 리미티드 인간 부갑상선 호르몬(pth)의 제형 및 그 제조 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3768177A (en) * 1972-08-02 1973-10-30 R Thomas Educational device
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US4016314A (en) * 1975-06-26 1977-04-05 Hallco Inc. Embroidered fruit bowl wall hanging and kit for making same
US4199060A (en) * 1978-07-20 1980-04-22 Howard Hardware Products, Inc. Lock installation kit
US4424278A (en) * 1981-11-16 1984-01-03 Research Corporation Cancer detection procedure using an acyl carrier protein
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
JP3090353B2 (ja) * 1991-09-17 2000-09-18 旭化成工業株式会社 パラチロイドホルモン類含有経鼻投与用乳剤
WO1993011785A1 (en) * 1991-12-09 1993-06-24 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
IT1255723B (it) * 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione

Also Published As

Publication number Publication date
EP1880732A1 (en) 2008-01-23
EP0735896B1 (en) 2007-10-03
DE69435033T2 (de) 2008-05-29
PT735896E (pt) 2007-12-07
ATE374621T1 (de) 2007-10-15
DE69435033D1 (de) 2007-11-15
HUT74381A (en) 1996-12-30
DK0735896T3 (da) 2008-02-04
ES2293637T3 (es) 2008-03-16
LV11731B (en) 1997-08-20
HU9601721D0 (en) 1996-08-28
CA2179207A1 (en) 1995-06-29
CN1116897C (zh) 2003-08-06
WO1995017207A1 (en) 1995-06-29
NO324905B1 (no) 2007-12-27
LV11731A (lv) 1997-04-20
NO962634D0 (no) 1996-06-20
NO962634L (no) 1996-06-20
FI962593A (fi) 1996-08-19
KR100398461B1 (ko) 2004-03-20
BR9408398A (pt) 1997-08-12
AU681737B2 (en) 1997-09-04
CZ184296A3 (en) 1997-01-15
HK1010336A1 (en) 1999-06-17
JP3065662B2 (ja) 2000-07-17
CA2179207C (en) 2000-11-14
CN1142772A (zh) 1997-02-12
NZ277463A (en) 1997-03-24
JPH09506869A (ja) 1997-07-08
US5496801A (en) 1996-03-05
EP0735896A1 (en) 1996-10-09
AU1269895A (en) 1995-07-10
PL315158A1 (en) 1996-10-14
FI120291B (fi) 2009-09-15
SK82896A3 (en) 1997-01-08

Similar Documents

Publication Publication Date Title
FI962593A0 (fi) Lisäkilpirauhasen hormonikoostumukset
EP0619119A4 (en) COMPOSITION BASED ON STABILIZED PARATHYROIDIAN HORMONE.
ES2055845T3 (es) Composicion farmaceutica para el tratamiento de la osteoporosis.
AU5561686A (en) Method of increasing bone mass
UA72884C2 (uk) Стабілізовані розчини паратирину
NO950123D0 (no) Paratyreoidea hormonforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende disse
BR9402902A (pt) Hormônio paratiróideo e raloxifeno, compostos e formulação farmacêutica.
DE69307977D1 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
IE882671L (en) Stabilised human protein formulation
NO891007D0 (no) Farmasoeytiske polypeptidholdige preparater.
DE69434588D1 (de) Verzögerte Freigabe von Insulinotropin (GLP-1)
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
IL140140A0 (en) Thyroid hormone analogues and methods for their preparation
GB9203299D0 (en) Cosmetic and/or pharmaceutical compositions and methods for their use
HU9302971D0 (en) Chewable antacid preparations
SE8803935L (sv) Laekemedelskomposition
GB2251188B (en) Drug delivery system comprising a lysophosphoglycerolipid
HRP20000781B1 (en) Effervescent preparations
IL87778A0 (en) Pharmaceutical compositions containing stabilized therapeutically active proteins and their preparation
FR2684878B1 (fr) Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
HK135494A (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient
EP0265338A3 (en) Stable therapeutical compositions based on hydrophobic vegetable oil, and process for preparing them
EP0175323A3 (en) Biologically active peptides, processes for preparing them and pharmaceutical compositions
EP0348664A3 (en) Pharmaceutical compositions containing monoacetoacetins for treating tumours
JPS5223586A (en) Carrier for fixing physiologically active material

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: ASTRA AB

PC Transfer of assignment of patent

Owner name: NPS PHARMACEUTICALS, INC.

Free format text: NPS PHARMACEUTICALS, INC.

FG Patent granted

Ref document number: 120291

Country of ref document: FI

MA Patent expired